View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 18, 2020

Dexamethasone: the first drug to improve survival chances for Covid-19 patients

By Allie Nawrat

On 16 June, the primary investigators of the UK’s RECOVERY trial announced that the commonly used, low-price corticosteroid dexamethasone has proven to be a potentially life-saving new treatment option for those critically ill with Covid-19 and requiring respiratory support.

It’s low cost, wide availability and easy administration is what makes dexamethasone’s success in Covid-19 patients on oxygen or ventilators so special.

The UK Government’s chief scientific adviser Sir Patrick Vallance stated: “It is particularly exciting as this is an inexpensive, widely available medicine. This is a ground-breaking development in our fight against the disease.”

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology